Peptide, New Chemical Entity (NCE);

Mechanism of Action: Formation of membrane pores;

Primary Indication: Triple Negative Breast Cancer;

Follow-up Indications: Other hard to treat cancers, including Ovarian Cancer;

Licensed from: Kings College London;

Published research: "Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer" Chen, C. H., Liu, Y. H., Eskandari, A., Ghimire, J., Lin, L. C., Fang, Z. S., Wimley, W. C., Ulmschneider, J. P., Suntharalingam, K., Hu, C. M. J. & Ulmschneider, M. B., (2022), Advanced Science. 9, 13 2105506. DOIs: https://doi.org/10.1002/advs.202105506

Review: "Development of membrane-active peptide therapeutics in oncology" Chen, C. H., Zan, B., Ulmschneider, J. P., Wimley, W. C., Lu, T. K. Ulmschneider, M. B., Zhou, L. (2023) Journal of Peptide Science DOIs: https://doi.org/10.1002/psc.3482

Patents: PCT patent family applications: WO 2021/069913; WO 2022/074402